Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) received marketing authorization for tagitanlimab from China's National Medical Products Administration, a Monday bourse filing by the biopharmaceutical firm said.
The authorization allows the use of the drug in combination with cisplatin and gemcitabine for the first-line treatment of patients with recurrent or metastatic nasopharyngeal cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments